4.11
+5.66%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Revelation Biosciences
From its filings with the US Securities and Exchange Commission
Revelation Biosciences is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker REVB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $8.9m. At that date it held total assets of $11.6m and shareholders' equity of $8.9m.
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (“AKI”) and GEM-CKD as a treatment for chronic kidney disease (“CKD”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.
Our common stock and warrants sold in our initial public offering (“Public Warrants”) are listed on The Nasdaq Stock Market, LLC (“Nasdaq”) under the ticker symbol “REVB” and “REVBW,” respectively.
Following the annual meeting of stockholders and determination by the Board of Directors on the reverse split ratio, we filed a Certificate of Amendment which effected a 1-for-3 reverse stock split of our outstanding shares of common stock effective as of July 7, 2025. Additionally, we filed a Certificate of Amendment effective which effected a 1-for-4 reverse stock split of our outstanding shares of common stock effective as of January 28, 2026, .
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Oct 2020
- Employees
- 14
- Website
- revbiosciences.com ↗
- Head office
- 4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. James RolkeChief Executive Officer, Co-Founder, Director, since 2020$813,226
- Mr. Chester ZygmontChief Financial Officer$564,006
- Ms. Jennifer CarverIndependent Director$60,000
- Dr. Lakhmir ChawlaIndependent Director$60,000
- Mr. Jess RoperIndependent Director$60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Revelation Biosciences focuses on immunologic-based therapies for disease prevention and treatment.
- PHAD, the active ingredient in their therapies, stimulates Toll-like receptor 4 (TLR-4).
- REVTx-300 targets acute and chronic organ injury and disease prevention.
Weaknesses
- The company has only 14 employees, indicating limited operational capacity.
- Revelation Biosciences is a clinical-stage company with no commercial products yet.
- Their IPO was on 8 October 2020, showing recent market entry.
Opportunities
- REVTx-100 addresses healthcare-associated bacterial infections from surgery and antibiotic resistance.
- REVTx-200 offers intranasal therapy combined with traditional IM vaccines.
- REVTx-99b targets food allergies, a growing market segment.
Threats
- The biotechnology sector faces intense competition for immunologic therapies.
- Regulatory hurdles may delay approval of clinical-stage therapies.
- PHAD-based therapies require extensive clinical trials for safety validation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.